Azenta, Inc. (Nasdaq: AZTA) has been chosen by The Lupus Research Alliance and its clinical research affiliate Lupus Therapeutics to revolutionize lupus research and drug discovery! Azenta will be the exclusive provider of sample management services such as collection kit design, laboratory services, logistics, and biorepository storage for the Lupus Nexus patient registry component. This is an incredible opportunity to make a lasting impact on lupus research and the patients who suffer from it.
The Lupus Nexus is a revolutionary, patient-centred research initiative that will bring together highly curated clinical data, patient-reported information, biological specimens and raw analysed data under one roof.
Supported through Azenta, the Lupus Landmark Study – the largest prospective observational study in lupus to date – is set to launch in 2023 and will recruit 3,500 adults diagnosed with systemic lupus erythematosus (SLE), providing an unprecedented glimpse into life with lupus. By curating this invaluable resource, the Lupus Nexus will be a hub for lupus research, shaping the future of lupus treatment and care.
Azenta is delighted to partner with the Lupus Research Alliance in order to create Lupus Nexus, a revolutionary repository which stores vital data and biopsies to aid research on systemic lupus erythematosus.
This noteworthy collaboration between the Lupus Research Alliance and Lupus Therapeutics has the capability to revolutionize lupus treatment, and Azenta is proud to have a key role in making this project a reality. According to Kathi Shea, Azenta’s Vice President of Repository and Innovation, this partnership promises to have a huge impact on lupus research.
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a global leader in life sciences solutions that accelerates impactful breakthroughs and therapies. Our comprehensive cold-chain sample management solutions and genomic services help power the success of the world’s top pharmaceutical, biotech, academic, and healthcare institutions. Whether it’s drug development, clinical research, or advanced cell therapies, our advanced solutions allow for faster, more efficient progress that can change the world.
Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe and Asia.